Ocular Therapeutix, Inc. Announces Phase 2 Study Results for Sustained Release Dexamethasone

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. announces today the results of its Phase 2 sustained release dexamethasone (OTX-DP) study for the treatment of post-operative inflammation and pain. Ocular Therapeutix’s sustained release dexamethasone is administered as a one-time absorbable intracanalicular plug, designed with a four-week tapered release.

Help employers find you! Check out all the jobs and post your resume.